The study of the effects of oral N/L-type calcium channel blocker cilnidipine on urinary excretions of albumin and podocyte in Japanese hypertensive patients.

The study of the effects of oral N/L-type calcium channel blocker cilnidipine on urinary excretions of albumin and podocyte in Japanese hypertensive patients. - The study of the effects of oral N/L-type calcium channel blocker cilnidipine on urinary excretions of albumin and podocyte in Japanese hypertensive patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009209

Enrollment

Registered

2012-10-29

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertensive patients

Interventions

with cilnidipine for 24 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Japanese hypertensive patients with renin-angiotensin system inhibitor and calcium antagonist (except for cilnidipine) for more than 3 months without requirement of adding other antihypertensive agents SBP>130 mmHg, DBP>80 mmHg

Exclusion criteria

Exclusion criteria: acute illness or malignant tumors drug allergy with pregnant or breast feeding, or candidates with such situations patients who are judged as inappropriate for inclusion by their physicians

Design outcomes

Primary

Measure	Time frame
Changes in urinary excretions of albumin and podocyte between groups.	—

Secondary

Measure	Time frame
Changes in blood pressure control.	—

Countries

Japan

Contacts

Public ContactWakana Miura

Tokai University School of Medicine Division of Nephrology, Endocrinology and Metabolism

happy0897@gmail.com0463-93-1121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026